Valeant turned down Takeda-TPG takeover offer: WSJ


Good news for Valeant investors worried the company won’t find takers for the parts of its business it wants to jettison: It’s already found a pair interested in picking up the entire company. The only thing is, it turned its suitors down.

The Canadian pharma received--and rejected--a joint takeover approach this spring from Takeda and private-equity firm TPG, The Wall Street Journal’s sources say. It came shortly before the drugmaker appointed new CEO Joseph Papa--after channel-stuffing allegations, debt-default worries and political pricing pushback had decimated shares by about 90%.

Valeant, though, wanted to give its new chief exec a chance to take the company in a different direction, the sources told the Journal.

The transaction would have made sense for GI-focused Takeda, which planned to take the business Valeant purchased from Salix Pharmaceuticals in 2015 and leave most of the rest for TPG. Salix’s portfolio includes blockbuster wannabe Xifaxan, which Takeda initially lost out on when Valeant emerged victorious from a bidding war for the North Carolina drugmaker.

Those talks are now off the table, though, the WSJ notes, and Valeant hasn’t received any other offers for the entire company, either. Still, though, the interest is reassuring as the Quebec-based company weighs which pieces to offer up for sale. In recent weeks, reports have listed Obagi Medical Products, laggard cancer vaccine Provenge and controversial heart meds Isuprel and Nitropress as assets Valeant may cast off, and earlier this year, board member Bill Ackman suggested that spinning off eyecare division Bausch & Lomb could generate cash to pay down debt.

- read the WSJ story (sub. req.)

Special Report: The most influential people in biopharma today - 2016 - J. Michael Pearson - Valeant

Related Articles:
Embattled Valeant doesn't 'need to sell anything,' new CEO says
Valeant weighs sales of controversial heart meds, laggard Provenge: Bloomberg
Valeant investors fret as new Perrigo CEO slams Papa's performance
Hospitals want to know: Where are the discounts Valeant promised on jacked-up heart meds?
Aiming for redemption, Valeant reveals new drug pricing committee
Valeant files overdue 10-K, makes sweeping board changes in push for turnaround
It's official: Pearson out, Papa in as Valeant CEO
Valeant investors, shocked by lightweight guidance, aren't buying CEO Pearson's recovery plans